Relationship between the transcriptional expression of PIM1 and local control in patients with head and neck squamous cell carcinomas treated with radiotherapy

Purpose Proviral integration site for Moloney murine leukemia virus (PIMs) are proto-oncogenes encoding serine/threonine kinases that phosphorylate a variety of substrates involved in the regulation of cellular processes. Elevated expression of PIM-1 has been associated with poor prognosis in severa...

Descripción completa

Detalles Bibliográficos
Autores: León i Vintró, Xavier|||0000-0001-6286-630X, Garcia Lorenzo, J.|||0000-0002-6123-7808, Pujol-Olmo, Albert|||0000-0003-3273-1900, Juan Beltrán, Julia de|||0000-0002-5827-3533, Vásquez, Rosselin|||0000-0002-2483-9383, Quer, Miquel|||0000-0003-2563-6729, Camacho, Mercedes|||0000-0001-5970-3294
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:250782
Acceso en línea:https://ddd.uab.cat/record/250782
https://dx.doi.org/urn:doi:10.1007/s00405-021-07223-4
Access Level:acceso abierto
Palabra clave:PIM-1
Head and neck carcinoma
Radiotherapy
Local control
Biomarker
Descripción
Sumario:Purpose Proviral integration site for Moloney murine leukemia virus (PIMs) are proto-oncogenes encoding serine/threonine kinases that phosphorylate a variety of substrates involved in the regulation of cellular processes. Elevated expression of PIM-1 has been associated with poor prognosis in several types of cancer. There are no studies that have analyzed the response to radiotherapy in patients with head and neck squamous cell carcinoma (HNSCC) according to the expression of PIM-1. The aim of our study was to analyze the relationship between the transcriptional expression of PIM-1 and local response to radiotherapy in HNSCC patients. Methods We determined the transcriptional expression of PIM-1 in 135 HNSCC patients treated with radiotherapy, including patients treated with chemoradiotherapy (n=65) and bioradiotherapy (n=15).